Thus, we hypothesized that AS mutation in FGFR2 over stimulates downstream signaling pathways activated by WT receptor and further induces pathognomonic novel molecular pathways, which may account for the AS abnormalities not seen in CS. This evidence concerns the gene FGFR2 and Cowden syndrome 1.